Cancer Vaccine Institute News

The Cancer Vaccine Institute (CVI) is advancing the emerging field of cancer research, developing vaccines to intercept cancer before it becomes invasive. We have developed WOKVAC, a DNA-based vaccine designed to target three proteins - HER2, IGFBP-2, and IGF-1R - highly expressed in most Ductal Carcinoma In Situ (DCIS), a preinvasive form of breast cancer. Although not immediately life-threatening, 20% of DCIS lesions may progress to invasive cancer. Patients diagnosed with

Last week, the halls of the Cancer Vaccine Institute (CVI) buzzed with conversation, curiosity, and optimism as Congresswoman Pramila Jayapal (WA-07) visited for an inside look at the future of cancer treatment and prevention. Moving through the lab, Congresswoman Jayapal met with CVI researchers, toured the Institute’s laboratory spaces, and learned more about the impact cancer vaccines are having on human health. The CVI team walked Congresswoman Jayapal through how our wor

At one of the most influential gatherings in global cancer research, Dr. Nora Disis, Director of the Cancer Vaccine Institute (CVI), took center stage. She was selected to speak at the Presidential Select Symposium at the American Association for Cancer Research (AACR) Annual Meeting, which gathers scientists, health care professionals, clinicians, patients, and advocates from around the world to share advances in cancer research. The symposium, “Targeting Stage 0: Precision-

Last week, KING 5 News featured ongoing research at the Cancer Vaccine Institute (CVI) to develop COLOVAC , a preventive vaccine designed to stop colon cancer before it starts. The segment included interviews with CVI Director Dr. Nora Disis and Becky Bruhn, a Seattle resident whose recent cancerous polyp illustrates the importance of early detection and need for new prevention tools. Colon cancer remains one of the leading causes of cancer death in the United States, and rat

Dr. Denise Cecil, CVI Principal Scientist. PC: AP Photos Colon cancer is the second leading cause of cancer death in the United States, with diagnoses rising among adults under 55. In response, the Cancer Vaccine Institute (CVI) at UW Medicine is developing COLOVAC, a first-in-class vaccine designed to intercept colon cancer at its earliest stages, offering hope to those at the highest risk. Rising Colon Cancer Risk Colon cancer remains one of the most consequential cancers o